In the Clinical Review entitled “Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma: A Systematic Review,” published in the March 27, 2013, issue of JAMA (2013;309:1278-1288. doi:10.1001/jama.2013.2049), a clarification should be made in 2 places. On page 1281, under the heading “Rhinitis,” the third sentence should read “The majority of studies (94%) demonstrated greater improvement in the sublingual immunotherapy groups vs placebo.” In Table 1, second row, “Rhinitis or rhinoconjunctivitis symptoms scores,” in column 7, “Findings,” should read “The majority of studies showed greater improvement in symptoms in the sublingual immunotherapy group vs placebo.” This article has been corrected online.
Clarification of Data. JAMA. 2013;310(6):647. doi:10.1001/jama.2013.48989
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.